Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab

Biologics: Targets and Therapy

Volumn 10, Issue , 2016, Pages 53-58

  Benucci, Maurizio ^a   Meacci, Francesca ^a   Grossi, Valentina ^a   Infantino, Maria ^a   Manfredi, Mariangela ^a   Bellio, Emanuele ^a   Bellio, Valerio ^a   Li Gobbi, Francesca ^a   Bazzichi, Laura ^b   Moscato, Paolo ^c   Caputo, Dario ^c   Saviola, Gianantonio ^d   Talotta, Rossella ^e   Sarzi Puttini, Piercarlo ^e   Atzeni, Fabiola ^f  

^a Ospedale San Giovanni di Dio   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d IRCCS   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Antibodies anti TCZ; TCZ drug level; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DRUG ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; IMMUNOGENICITY; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84962535857     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S97234     Document Type: Article

References (21)

1. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006; 8 Suppl 2:S3.
2. Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther. 2006; 8 Suppl 2:S4.
3. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6):784-788.
4. Robak T, Wierzbowska A, Blasinska-Morawiec M, Korycka A, Blonski JZ. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Mediators Inflamm. 1999;8(6):277-286.
5. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin-6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232-234.
6. Straub RH, Muller-Ladner U, Lichtinger T, Scholmerich J, Menninger H, Lang B. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol. 1997;36(12): 1298-1303.
7. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, doubleblind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46(12):3143-3150.
8. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
9. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo controlled, randomised trial. Lancet. 2008;371(9617):987-997.
10. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-2980.
11. Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013;12(7):703-708.
12. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1-2):1-16.
13. Kaliyaperumal A, Jing S. Immunogenicity assessment of therapeutic proteins and peptides. Curr Pharm Biotechnol. 2009;10(4):352-358.
14. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43-50.
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-524.
16. Sigaux J, Hamze M, Daien C, et al. The lack of antidrug antibodies among patients treated with tocilizumab: a clue to good efficacy profiles when used in monotherapy? Ann Rheum Dis. 2015;74(Suppl 2):1050.
17. Rodriguez-Muguruz S, Quirant B, Teniente A, et al. Tocilizumab serum levels and antidrug antibodies and its relationship with disease activity in rheumatic disease. Ann Rheum Dis. 2015;74(Suppl2):731.
18. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther. 2010;32(9):1597-1609.
19. Ogata A, Amano K, Dobashi H, et al. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. J Rheumatol. 2015;42(5):799-809.
20. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis. 2016;75(1):68-74.
21. Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancer. Pharmacol Ther. 2014;141(2):125-139.